PressDecember 2, 2021 Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia
PressDecember 2, 2021 Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note
PressDecember 1, 2021 MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin
PressNovember 30, 2021 Clairvoyant Therapeutics Raises More Than $3 Million in Seed Financing, Adds Bench Strength to Senior Leadership Team
PressNovember 29, 2021 Albert Labs Receive Conditional Approval for CSE Listing & Appoint Chrystal Capital Partners to Advise on European Listing
PressNovember 29, 2021 Biomind Labs Announces Design of a Pharmaceutical Form for Psychedelic Drug Delivery Using 3D Printing
PressNovember 22, 2021 Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results and Provides Business Update
PressNovember 19, 2021 Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders
PressNovember 18, 2021 Filament Health Announces Co-Development and Exclusive Licensing Agreement with Entheotech Bioscience
PressNovember 18, 2021 Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods
PressNovember 16, 2021 MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights
PressNovember 15, 2021 atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
PressNovember 12, 2021 MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist
PressNovember 11, 2021 Alto Neuroscience Announces Publication in Nature Neuroscience Highlighting Superiority of Data-Driven Framework for Mapping Human Neurobiology Domains
PressNovember 8, 2021 Braxia Scientific CEO Dr. Roger McIntyre to Deliver Keynote Address at Wonderland: Miami
PressNovember 8, 2021 Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
PressNovember 4, 2021 Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
